TY  - JOUR
AU  - Coyle, L
AU  - Morley, NJ
AU  - Rambaldi, A
AU  - Mason, KD
AU  - Verhoef, G
AU  - Furness, CL
AU  - Zhang, A
AU  - Jung, AS
AU  - Cohan, D
AU  - Franklin, JL
Y2  - 2020/12/14
Y1  - 2020/05/31
SN  - 1042-8194
UR  - http://hdl.handle.net/11343/254224
AB  - The phase 2 portion of this open-label phase 2/3 study assessed the efficacy and safety of blinatumomab as second salvage for aggressive relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) following platinum-based first salvage chemotherapy. Forty-one patients with aggressive disease (32% relapsed; 68% refractory) enrolled and received stepwise blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2; 19 (46%) completed cycle 1 and 3 (7%) completed cycle 2. The overall response rate after 12 weeks was 37%, including 9 (22%) complete metabolic responses. Eight (20%) patients (all responders) subsequently received stem cell transplants. Grade ≥3 adverse events were reported in 29 (71%) patients. Grade 3 cytokine release syndrome occurred in one patient. Grade 3 neurologic events occurred in 10 (24%) patients; all resolved. Blinatumomab monotherapy appears effective as second salvage therapy in patients with r/r aggressive B-NHL. Trial registration: NCT02910063.
LA  - English
PB  - TAYLOR & FRANCIS LTD
T1  - Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
DO  - 10.1080/10428194.2020.1759055
IS  - Leukemia and Lymphoma
VL  - 61
IS  - 9
SP  - 2103-2112
ER  -